Triple-negative breast cancer

Breast Cancer Research

Volumn 12, Issue SUPPL. 2, 2010, Pages

  Chacón, Reinaldo D ^a   Costanzo, María V ^a  

^a INSTITUTO ALEXANDER FLEMING   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; GEFITINIB; GELDANAMYCIN; GEMCITABINE; IRINOTECAN; IXABEPILONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; OXALIPLATIN; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB; TANESPIMYCIN; TAXANE DERIVATIVE; TEMSIROLIMUS; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER GRADING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; PROGRESSION FREE SURVIVAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; ENZYMOLOGY; FEMALE; METABOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 78650911210     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2574     Document Type: Review

References (78)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
2. Lakhani S, Van De Vijver M. The patology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER2, and p53 mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318. 10.1200/JCO.2002.09.023, 11981002.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, . American Society of Clinical Oncology College of American Pathologists American Society of Clinical Oncology/College of American Pathologist guideline recommendation for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775, 17159189, American Society of Clinical Oncology College of American Pathologists.
5. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapy in breast cancer: the HER-2/neu gen and protein. Mol Cell Proteomics 2004, 3:379-398. 10.1074/mcp.R400001-MCP200, 14762215.
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brwon PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor sub-types in independent gene expression data set. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenchikov A, Williams C, Zhu SX, Lønning PE, Børreson-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
9. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32. 10.1002/cncr.22381, 17146782.
10. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D. How basal are triple-negative breast cancer. Int J Cancer 2008, 123:236-240. 10.1002/ijc.23518, 18398844.
11. Sotiriou C, Phil D, Pusztaj J. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like sub-type of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
13. Livasy CA, Karaca C, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19:264-271. 10.1038/modpathol.3800528, 16341146.
14. Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS. Are triple negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007, 9:404. 2246182, 18279542, 10.1186/bcr1827.
15. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
16. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Cluade J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maurgard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Schermeck S, Sobol H, et al. Breast Cancer Linkage Consortium Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180. 10.1158/1078-0432.CCR-04-2424, 16033833, Breast Cancer Linkage Consortium.
17. Collett K, Stefansonn IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen S, Foulkes WD, Akslen LA. A basal epithelial phenotype is more frequent in interval breast cancer compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005, 14:1108-1112. 10.1158/1055-9965.EPI-04-0394, 15894660.
18. Dent R, Trudeau M, Pritchard KL, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
19. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadyuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281. 10.1200/JCO.2007.14.4147, 18250347.
20. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Marten JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68:3108-3114. 10.1158/0008-5472.CAN-07-5644, 18451135.
21. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113:2638-2645. 2835546, 18833576, 10.1002/cncr.23930.
22. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastasic breast carcinoma. Cancer 2003, 97:2972-2977. 10.1002/cncr.11436, 12784331.
23. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR) negative, and HER-2 negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007, 109:1721-1728. 10.1002/cncr.22618, 17387718.
24. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110:876-884. 10.1002/cncr.22836, 17620276.
25. Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J, Hobbs G. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 2008, 17:3319-3324. 10.1158/1055-9965.EPI-08-0544, 19064545.
26. Solin LJ, Hwang W, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer 2009, 9:96-100. 10.3816/CBC.2009.n.018, 19433390.
27. NCCN Practice Guidelines in Oncology - V.2. - BINV 8. , http://http//www.nccn. org/professionals/physician_gls/f_guidelines.asp
28. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Golstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506. 10.1056/NEJMoa071167, 17928597.
29. Loesch D, Greco F, O'Shaughnessy J. A randomized, multicenter, phase III trial comparing regimens of doxorubicin + cyclophosphamide (AC) followed by paclitaxel to doxorubicin + paclitaxel (AP) followed by weekly paclitaxel (wP) as adjuvant therapy for patients with high-risk, operable breast cancer. J Clin Oncol 2007, 25(Suppl 18):Abstract 517.
30. Hudis C, Citron M, Berry D. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective [abstract 41]. Breast Cancer Res Treat 2005, 94(Suppl 1):S20.
31. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
32. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
33. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009, 27:526-534. 10.1200/JCO.2007.14.2646, 19075286.
34. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009, 9:29-33. 10.3816/CBC.2009.n.005, 19299237.
35. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilona plus capecitabine for metástasis breast cáncer progressing after antracyclines and taxane treatment. J Clin Oncol 2007, 25:5210-5217. 10.1200/JCO.2007.12.6557, 17968020.
36. Roche H, Li RK, Ro J. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Cancer Res 2009, 69(Suppl 2):Abstract 2015.
37. Farmer H, McCabe N, Lord CJ, Tutt AN, Jonson DA, Richardson TB, Santatosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smtih GC, Ashworth A. Targeting the DNA repair defect in BRCA1 mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
38. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad5 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275:23899-23903. 10.1074/jbc.C000276200, 10843985.
39. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819. 10.1038/nrc1457, 15510162.
40. Garber JF, Richardson A, Harris LN. Neo-adjuvant cisplatin (CDDP) in 'triple-negative' breast cancer (BC) [abstract 308]. Breast Cancer Res Treat 2006, 100(Suppl 1):S32.
41. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple negative breast cancer. Annals Oncol 2008, 19:1847-1852.
42. Yi S, Uhm J, Cho E. Clinical outcomes of metastatic breast cáncer patients with triple-negative phenotype who received platinum-containing chemotherapy [abstract 1086]. J Clin Oncol 2008, 26(Suppl 15):43s.
43. Chia JW, Ang P, See H. Triple-negative metastasic/recurrent breast cancer: treatment with paclitaxel/carboplatin combination chemotherapy [abstract 1086]. J Clin Oncol 2007, 25(Suppl 18):53s.
44. Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. Cancer J 2008, 14:343-351. 10.1097/PPO.0b013e31818d839b, 19060597.
45. Goffin JR, Straume O, Chappuis PO, Brunet JS, Bégin LR, Hamel N, Wong N, Akslen LA, Foulkes WD. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRACA1 mutations and an adverse outcome following breast cancer. Br J Cancer 2003, 89:1031-1034. 2376955, 12966421, 10.1038/sj.bjc.6601195.
46. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
47. Miles D, Chan A, Romieu G. Randomized, doubled-blind, placebo-controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA 1011]. J Clin Oncol 2008, 26(Suppl 15):1008s.
48. Robert N, Dieras V, Glaspy J. Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009, 27(Suppl 15):Abstract 1005.
49. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodinamic relationship. Clin Cancer Res 2003, 9:327-337.
50. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU 11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:757-766.
51. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK. SU 11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20:757-766. 10.1023/B:CLIN.0000006873.65590.68, 14713109.
52. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816. 10.1200/JCO.2007.14.5375, 18347007.
53. Barrios C, Liu M, Lee S. A phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER 2 negative advanced breast disease (SUN 1107) [abstract 46]. Proceedings of the San Antonio Breast Cancer Symposium 2009, 32nd Annual San Antonio Breast Cancer Symposium http://www.sabcs.org.
54. Baselga J, Roche H, Costa F. SOLTI 0701: a multinacional double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer [abstract 45]. Proceedings of the San Antonio Breast Cancer Symposium 2009, 32nd Annual San Antonio Breast Cancer Symposium http://www.sabcs.org.
55. Gradishar W, Kaklamani V, Prasad Sahoo T. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as a first line therapy in patients with locally recurrent or metastatic breast cancer [abstract 44]. Proceedings of the San Antonio Breast Cancer Symposium 2009, 32nd Annual San Antonio Breast Cancer Symposium http://www.sabcs.org.
56. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swasiland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribosa) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
57. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434:913-917. erratum Nature 2007, 447:346, 10.1038/nature03443, 15829966.
58. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers K. Selective inhibition of BRCA-2 deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008, 14:3916-3925. 10.1158/1078-0432.CCR-07-4953, 18559613.
59. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J. Phase II trial of the oral PARP inhibitor olaparib-deficient advanced breast cancer. J Clin Oncol 2009, 27(Suppl 15):CRA501.
60. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, OssovsKaya V, Sherman B, Bradley C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27(Suppl 15):Abstract 3.
61. Corkery B, Crown J, Clynes M, O'Donavan N. Epidermal growth factor receptor as a potential therapeutic target in triple negative breast cancer. Ann Oncol 2009, 20:862-867. 10.1093/annonc/mdn710, 19150933.
62. Pal SK, Mortimer J. Triple negative breast cancer: novel therapies and new directions. Maturitas 2009, 63:269-274. 10.1016/j.maturitas.2009.06.010, 19632796.
63. Gholam D, Chebib A, Hauteville D, Bralet MP, Jasmin C. Combined paclitaxel and cetuximab archieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anticancer Drugs 2007, 18:835-837. 10.1097/CAD.0b013e3280adc8e0, 17581308.
64. Carey L, Rugo H, Marcom S. TBCRC 001: EGFR inhibition with cetuximab added to carboplatinum in metastatic TNBC (basal like). J Clin Oncol 2008, 26(suppl 15):Abstract 1009.
65. O'Shaughnessy J, Weskstein D, Vukelja S. Results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):S32.
66. Clinical Trials. , http://www.ClinicalTrials.gov
67. Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauldea S, Marimón I, Tabernero JM, Koehler MT, Rojo F. Phase II and pharmacodynamic study of Gefitinib in patients with advanced breast cancer. J Clin Oncol 2005, 23:5323-5333. 10.1200/JCO.2005.08.326, 15939921.
68. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hermandez-Boussard T, Livasy C, Cowen D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immnunohistochemical and clinical characterization of the basal like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
69. Conlin AK, Seidman AD. Beyond cytotoxic chemotherapy for the first line treatment of HER 2-negative, hormone insensitive metastatic breast cancer: current status and future opportunities. Clin Breast Cancer 2008, 8:215-223. 10.3816/CBC.2008.n.024, 18650151.
70. Verbeek B, Vroom T, Adriansen-Slot S, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996, 180:383-388. 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N, 9014858.
71. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally ative small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type triple negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326. 10.1007/s10549-006-9463-x, 17268817.
72. Finn R, Bengala C, Ibrahim N. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA. Cancer Res 2009, 69(Suppl 2):Abstract 3118.
73. Saal LH, Holm K, Maurer M, Merneo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormonoreceptors, node metastasis and ERBB2 and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559. 10.1158/0008-5472-CAN-04-3913, 15805248.
74. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Michaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND. J Clin Oncol 2009, 27:4536-4541. 10.1200/JCO.2008.21.3033, 19687332.
75. Whitesell L, Mimmaugh E, De Costa B, Myers CE, Neckers LM. Inhibition of HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic trasnformation. Proc Natl Acad Sci U S A 1994, 91:8324-8328. 44598, 8078881, 10.1073/pnas.91.18.8324.
76. Modi S. Heat shock protein 90 inhibition: a novel strategy for the treatment of HER2-positive breast cancer. Proceedings of the San Antonio Breast Cancer Symposium 2009, 32nd Annual San Antonio Breast Cancer Symposium http://www.sabcs.org.
77. Caldas-Lopez E, Cerchietti L, Ahn J, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchine E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of maliganancy induces complete responses in triple negative breast cancer models. Proc Natl Acad Sci U S A 2009, 106:8368-8373. 2688867, 19416831, 10.1073/pnas.0903392106.
78. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to triple negative state and unfavorable prognosis in breast cancer patients. Med Oncol Epub ahead of print.